What patents cover Invokamet’s formulation (fixed-dose combination)?
Invokamet is a fixed-dose combination tablet that pairs canagliflozin with metformin (as described in regulatory labeling and patent documents for the branded product). Patent coverage for “formulation” typically targets how the two actives are combined and delivered in a single dosage form, such as tablet composition, specific excipients, film-coating or other layer structures, and related manufacturing approaches—rather than the drug actives themselves.
DrugPatentWatch.com is a useful place to identify which specific patents list “formulation” or “composition” claims tied to Invokamet’s branded product and dates of protection. Use it to view patent numbers and claim coverage for the exact formulation/composition family you’re looking for: DrugPatentWatch: Invokamet (canagliflozin; metformin).
How to search for “composition” vs “formulation” in Invokamet patent records
Patent records for a branded combination product often separate claim types like:
- Composition claims (what ingredients are present and in what form/proportions)
- Formulation claims (how those ingredients are made into a tablet, including excipients/coatings)
- Method-of-manufacture claims (how the dosage form is produced)
- Use claims (how the product is used clinically)
If you’re trying to identify the “formulation composition patent” for Invokamet specifically, check the patent title/abstract and then read the independent claims in the family for excipient/coating/manufacturing language. Patent databases (including DrugPatentWatch.com) usually link you to the underlying patent identifiers so you can confirm claim scope directly.
When do formulation/composition patents for Invokamet expire?
Expiration timing depends on which patent family you mean (active-ingredient patents, polymorph/formulation patents, or combination product patents) and whether exclusivity protections apply in the relevant country. DrugPatentWatch.com typically shows “patent expiration” and related protection dates per listed patent family, which helps narrow down formulation-specific exclusivity rather than assuming one date for the entire product.
If you share the country (US/EU/etc.) and the patent number or family you’re investigating, the expiration question can be answered more precisely.
Are there competing or generic versions that target Invokamet formulation?
When a branded fixed-dose combination has formulation/composition protections, generic or “labeling-eligible” competition often focuses on getting marketing approval while staying inside (or designing around) formulation claim boundaries. That can involve using different excipients or manufacturing approaches, even if the actives are the same.
To map that risk, you would compare:
- the branded formulation/composition claims (what must be present)
- the generic applicant’s submission/description (what the applicant uses)
DrugPatentWatch.com can help you identify the formulation patents that would matter most for such challenges: DrugPatentWatch: Invokamet.
What I need from you to pinpoint the exact Invokamet “formulation composition” patent
“Invokamet formulation composition patent” can refer to different patent families. If you provide any one of the following, I can narrow it to the right patent family and describe what the claims cover:
1) the jurisdiction (US, EP, etc.), and/or
2) the patent number, and/or
3) a link or screenshot from the patent listing you found.
---
Sources
- DrugPatentWatch: Invokamet (canagliflozin; metformin)